Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
467
datasets available to search
ShareScore release 0.9.0
Dataset results
467 results for “Trial Data”
Crop performance, aerial, and satellite data from multistate maize yield trials
<p>Accurate genotype-specific early yield estimates at fields and plots offer potential benefits to farmers in optimizing their agronomic practices, breeders in screening hundreds and thousands of varieties, and policymakers in decisions contributing to the overall improvement of agriculture and food production systems. Effective, generalizable approaches to track plant growth and predict yield at the individual plot level require large matched datasets of remote sensing and ground truth data collected across multiple environments. Low-altitude drone flights are increasingly being used to collect data from field evaluations of new crop varieties, while satellite imagery is being explored to track yield and management practices at the regional and field scales. Despite their lower spatial resolution, satellite platforms exhibit multiple logistical and technical advantages in scalability and accessibility, and could facilitate plot-level predictions, especially with steadily improving spatial resolution. However, genotype-specific, plot-level, high-resolution satellite images from multiple environments integrated with the ground truth measurements are not yet publicly available. Here we generated, described, and evaluated a set of more than 20,000 plot-level images of over 80 hybrid maize (Zea mays) varieties grown in six locations across the US corn belt under various management practices collected from (near simultaneous) satellite and drone flights integrated with ground truth measurements of crop yield. Of the six baseline models examined, models employing data collected from satellite images often matched or exceeded the performance of models employing data collected from drones for both within-environment and cross-environment yield prediction. Large, multimodal, multi-environment, genetically diverse training datasets such as those generated in this study, along with more complex models could help unlock the power of satellite imagery as an important new addition to the tool of farmers, plant geneticists, crop breeders, and policymakers.</p>
Data for the project 'Feasibility and Effectiveness of a Personalized Home-Based Motor-Cognitive Training Program in Community-Dwelling Older Adults: a Pragmatic Pilot Randomized Controlled Trial'
<p>Data for the project 'Feasibility and Effectiveness of a Personalized Home-Based Motor-Cognitive Training Program in Community-Dwelling Older Adults: a Pragmatic Pilot Randomized Controlled Trial' including four complete datasets with all variables collected in this project and a corresponding README file ('README-File_Data_Feasibility and Effectiveness of a Personalized Home-Based Motor-Cognitive Training Program in Community-Dwelling Older Adults: a Pragmatic Pilot Randomized Controlled Trial.txt'). The latter provides (1) general information, (2) sharing and access information, (3) data and file overview, (4) methodological information, and (5) data-specific information.</p>
Field mosquito trapping data for UAV trial I in Nakasi, Fiji (2018)
<p>Number of <em>Aedes aegypti</em>, coloured and not coloured (UM) were recorded daily for each trap for all 4 releases. Cumulative mosquito count was calculated by tallying mosquitoes collected over the monitoring period. Total number of traps that caught <em>Aedes aegypti</em> were counted and recorded. Average mosquito catch per trap was calculated by dividing the total number of mosquitoes caught by the number of traps that captured <em>Aedes aegypti</em> for each day.</p>
Data from: Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double-blind, randomised, controlled, phase 3 trial
<p>Morbidity and mortality attributable to COVID-19 is devastating global health systems and economies. Bacillus Calmette Guérin (BCG) vaccination has been in use for many decades to prevent severe forms of tuberculosis in children. Studies have also shown a combination of improved long-term innate or trained immunity (through epigenetic reprogramming of myeloid cells) and adaptive responses after BCG vaccination, which leads to non-specific protective effects in adults. Observational studies have shown that countries with routine BCG vaccination programs have significantly less reported cases and deaths of COVID-19, but such studies are prone to significant bias and need confirmation. To date, in the absence of direct evidence, WHO does not recommend BCG for the prevention of COVID-19. This project aims to investigate in a timely manner whether and why BCG-revaccination can reduce infection rate and/or disease severity in health care workers during the SARS-CoV-2 outbreak in South Africa. </p> <p>These objectives will be achieved with a blinded, randomised controlled trial of BCG revaccination versus placebo in exposed front-line staff in hospitals in Cape Town. Observations will include the rate of infection with COVID-19 as well as the occurrence of mild, moderate or severe ambulatory respiratory tract infections, hospitalisation, need for oxygen, mechanical ventilation or death. HIV-positive individuals will be excluded. Safety of the vaccines will be monitored. A secondary endpoint is the occurrence of latent or active tuberculosis. Initial sample size and follow-up duration is at least 500 workers and 52 weeks. Statistical analysis will be model-based and ongoing in real time with frequent interim analyses and optional increases of both sample size or observation time, based on the unforeseeable trajectory of the South African COVID-19 epidemic, available funds and recommendations of an independent data and safety monitoring board. The study will be supported by a novel 3D lung organoid model of SARS-CoV-2 infection system that can mimic the cascade of immunological events after SARS-CoV-2 infection to determine and analyse the contribution of cellular components to the impact of BCG revaccination in this study.</p> <p>Given the immediate threat of the SARS-CoV-2 epidemic the trial has been designed as a pragmatic study with highly feasible endpoints that can be continuously measured. This allows for the most rapid identification of a beneficial outcome that would lead to immediate dissemination of the results, vaccination of the control group and outreach to the health authorities to consider BCG vaccination for all qualifying health care workers.</p>
Predicting Publication of Clinical Trials Using Structured and Unstructured Data
<p>This dataset (N=76,950) links metadata from ClinicalTrials.gov (a registry of clinical trials) and MEDLINE (a bibliographic database of academic journal articles), and can be used to model whether a clinical trial will get published or not.</p>
Biomass encounter rates limit the size scaling of feeding interactions: trial data
<p>Experimental trial data for the publication: Biomass encounter rates limit the size scaling of feeding interactions.</p>
Data for: To Tweet or Not to Tweet, That is the Question: A Randomized Trial of Twitter Effects in Medical Education
<p>This is the raw data for the manuscript: To Tweet or Not to Tweet, That is the Question: A Randomized Trial of Twitter Effects in Medical Education. The abstract for the study is as follows: </p> <p>Introduction: Many medical education journals use Twitter to garner attention for their articles. The purpose of this study was to test the effects of tweeting on article page views and downloads.</p> <p>Methods: The authors conducted a randomized trial using <em>Academic Medicine</em> articles published in 2015. Beginning in February through May 2018, one article per day was randomly assigned to a Twitter (case) or control group. Daily, an individual tweet was generated for each article in the Twitter group that included the title, #MedEd, and a link to the article. The link delivered users to the article’s landing page, which included immediate access to the HTML full text and a PDF link. The authors extracted HTML page views and PDF downloads from the publisher. To assess differences in page views and downloads between cases and controls, a time-centered approach was used, with outcomes measured at 1, 7, and 30 days.</p> <p>Results: In total, 189 articles (94 cases, 95 controls) were analyzed. After days 1 and 7, there were no statistically significant differences between cases and controls on any metric. On day 30, HTML page views exhibited a 63% increase for cases (M=14.72, SD=63.68) when compared to controls (M=9.01, SD=14.34; incident rate ratio=1.63, p=0.01). There were no differences between cases and controls for PDF downloads on day 30.</p> <p>Discussion: Contrary to the authors’ hypothesis, only one statistically significant difference in page views between the Twitter and control groups was found. These findings provide preliminary evidence that after 30 days a tweet can have a small positive effect on article page views.</p>
Zea mays MAGIC RIL population - field trial phenotyping data
<p>MIAPPE compliant ISA-tab files of the Zea mays MAGIC RIL population derived from eight genetically diverse founder lines.</p>
Data set from the 6G-SANDBOX platforms benchmarking and assessment for different documented trial networks - Oulu facility
<p>This data set covers core network and end-to-end measurements at the Oulu facility, part of the 6G-SANDBOX infrastructure.</p>
Data set from the 6G-SANDBOX platforms benchmarking and assessment for different documented trial networks - Malaga facility
<p>This data set covers core network and end-to-end measurements at the Malaga facility, part of the 6G-SANDBOX infrastructure.</p>
Data set from the 6G-SANDBOX platforms benchmarking and assessment for different documented trial networks - Berlin facility
<p>This data set covers core network and end-to-end measurements at the Berlin facility, part of the 6G-SANDBOX infrastructure.</p>
Data set from the 6G-SANDBOX platforms benchmarking and assessment for different documented trial networks - Athens facility
<p>This data set covers core network and end-to-end measurements at the Athens facility, part of the 6G-SANDBOX infrastructure.</p>
Data for: Sequential trial-curing of off-stoichiometric amine-epoxy thermosets with ionic liquids
<p>Data for the journal paper "Sequential trial-curing of off-stoichiometric amine-epoxy thermosets with ionic liquids".</p>
Raw data for the article: A Randomized Controlled Trial of Antithrombin Supplementation During Extracorporeal Membrane Oxygenation
<p><strong>Objectives: </strong>Supplementation of antithrombin might decrease the amount of heparin needed to achieve a given anticoagulation target during extracorporeal membrane oxygenation. However, exogenous antithrombin itself may increase the risk of bleeding. We conceived a study to evaluate the effect of antithrombin supplementation in adult patients requiring venovenous extracorporeal membrane oxygenation for respiratory failure on heparin dose, adequacy of anticoagulation, and safety.</p> <p><strong>Design: </strong>Prospective randomized controlled trial.</p> <p><strong>Setting: </strong>ICUs of two Italian referral extracorporeal membrane oxygenation centers.</p> <p><strong>Patients: </strong>Adult patients requiring venovenous extracorporeal membrane oxygenation for severe respiratory failure and unfractionated heparin for systemic anticoagulation.</p> <p><strong>Interventions: </strong>Before extracorporeal membrane oxygenation start, patients were randomized to either receive antithrombin concentrate to maintain a plasmatic level 80-120% (treatment) or not (control) during the extracorporeal membrane oxygenation course.</p> <p><strong>Measurements and main results: </strong>The primary outcome was the total amount of heparin required to maintain activated partial thromboplastin time ratio 1.5-2. Secondary outcomes were anti-factor Xa, the incidence of hemorrhagic and thrombotic events, and the amount of blood products transfused. Twenty-four patients in the treatment group and 24 in the control group were included in the intention-to-treat analysis. Antithrombin was 109.5% (93.0-123.0%) in the treatment group and 84.0% (68.5-98.0%) in the control group (p = 0.001). Supplementation of antithrombin did not decrease heparin dose (13.5 international units/kg/hr [9.6-17.9 international units/kg/hr] vs 15.1 international units/kg/hr [10.7-18.3 international units/kg/hr] in the treatment and control group, respectively; p = 0.33) and anti-Factor Xa levels (0.4 international units/mL [0.3-0.5 international units/mL] vs 0.3 international units/mL [0.2-0.5 international units/mL] in the treatment group and control group respectively; p = 0.65). Bleeding, blood product transfusions, and thrombosis were not different in the two groups.</p> <p><strong>Conclusions: </strong>Antithrombin supplementation may not decrease heparin requirement nor diminish the incidence of bleeding and/or thrombosis in adult patients on venovenous extracorporeal membrane oxygenation.</p>
Data from: Computer-aided X-ray screening for tuberculosis and HIV testing among adults with cough in Malawi (the PROSPECT study): a randomized trial and cost-effectiveness analysis
<p>Suboptimal tuberculosis (TB) diagnostics and HIV contribute to the high global burden of TB. We investigated costs and yield from systematic HIV-TB screening, including computer-aided digital chest X-ray (DCXR-CAD). Suboptimal tuberculosis (TB) diagnostics and HIV contribute to the high global burden of TB. We investigated costs and yield from systematic HIV-TB screening, including computer-aided digital chest X-ray (DCXR-CAD).</p> <p>In this open, three-arm randomised trial, adults (≥18 years) with cough attending acute primary services in Malawi were randomised (1:1:1) to standard-of-care (SOC); oral HIV testing (HIV screening) and linkage to care; or HIV testing and linkage to care plus DCXR-CAD with sputum Xpert for high CAD4TBv5 scores (HIV-TB screening). Participants and study staff were not blinded to intervention allocation, but investigator blinding was maintained until final analysis. The primary outcome was time to TB treatment. Secondary outcomes included proportion with same-day TB treatment; prevalence of undiagnosed/untreated bacteriologically-confirmed TB on day 56; and undiagnosed/untreated HIV. Analysis was done on an intention to treat basis. Cost-effectiveness analysis used a health-provider perspective. Between 15/11/2018-27/11/2019, 8236 were screened for eligibility, with 473, 492, and 497 randomly allocated to SOC, HIV, and HIV-TB screening arms; 53 (11%), 52 (9%), and 47 (9%) were lost to follow-up, respectively. At 56 days, TB treatment had been started in 5 (1.1%) SOC, 8 (1.6%) HIV-screening, and 15 (3.0%) HIV-TB screening participants. Median (IQR) time to TB treatment was 11 (6.5-38), 6 (1-22) and 1 (0-3) days (hazard ratio for HIV-TB vs. SOC: 2.86, 1.04-7.87), with same-day treatment of 0/5 (0%) SOC, 1/8 (12.5%) HIV, and 6/15 (40.0%) HIV-TB screening arm TB patients (p=0.03). At day 56, 2 SOC (0.5%), 4 HIV (1.0%), and 2 HIV-TB (0.5%) participants had undiagnosed microbiologically-confirmed TB. HIV screening reduced the proportion with undiagnosed or untreated HIV from 10 (2.7%) in the SOC arm to 2 (0.5%) in the HIV-screening arm (risk ratio [RR]: 0.18, 0.04-0.83), and 1 (0.2%) in the HIV-TB screening arm (RR: 0.09, 0.01-0.71). Incremental costs were US$3.58 and US$19.92 per participant screened for HIV and HIV-TB; the probability of cost-effectiveness at a US$1200/quality-adjusted life-year (QALY) threshold were 83.9% and 0%. Main limitations were the lower than anticipated prevalence of tuberculosis and short participant follow-up period; cost and quality of life benefits of this screening approach may accrue over a longer time horizon.</p> <p>DCXR-CAD with universal HIV screening significantly increased the timeliness and completeness of HIV and TB diagnosis. If implemented at scale this has potential to rapidly and efficiently improve TB and HIV diagnosis and treatment.</p>
Open Data_Remedial trial of sequential anoxic_oxic chemico_biological treatment for decontamination of extreme hexachlorocyclohexane concentrations in polluted soil
<p>Open data sheet used for the preparation of the publication "Remedial trial of sequential anoxic/oxic chemico-biological treatment for decontamination of extreme hexachlorocyclohexane concentrations in polluted soil" containing graphs and other data</p>
Growth, mortality and infection success data from Procambarus virginalis infection trials
<p><span>The dataset STRIVE consists of two files which contain: </span><span>(1) measurements of wet weight (g) and total length (mm) of juvenile marbled crayfish (<em>Procambarus virginalis</em>) used in infection trials performed at the Department of Biology, Faculty of Science, University of Zagreb; and (2) records of juvenile marbled crayfish mortality and detection of crayfish plague pathogen (<em>Aphanomyces astaci</em>) in individuals used in infection trials under (1). Two sets of experiments were performed: Experiment 1 where juvenile marbled crayfish were continuously exposed to two concentrations of <em>A. astaci</em> (7500 and 15000 zoospore/mL) and Experiment 2 where juveniles were exposed to a higher pathogen load (15000 zoospores/mL) but under differing feeding regime (once a week vs. five times a week). In both experiments, all infected groups had respective non-infected control groups. Infections were repeated every two weeks, and individuals were measured and weighed before consecutive infections. Wet weight was measured using a digital scale, while the total length was measured from photographs using the image processing program, ImageJ. All crayfish were tested at the end of experiments for the presence of <em>A. astaci</em> in the crayfish cuticle using PCR-based assay with specific primers which amplify the ITS (Internal Transcribed Spacer) region of the <em>A. astaci</em> 5.8 rRNA gene. </span></p>
REGAIN trial intervention development process evaluation data
<p><strong>Background</strong>: Up to half of people hospitalised with COVID-19 report diverse and persistent symptoms affecting quality of life for months and sometimes years after discharge (long-COVID). We describe the development of an online group exercise and behavioural support intervention for people who continue to experience such physical and/or emotional health problems more than three months after hospital discharge. <br><br><strong>Methods</strong>: Intervention development was informed by the Medical Research Council framework for complex interventions. Our multidisciplinary team of academics, clinicians, and people with long-COVID, had collective expertise in the development and testing of complex interventions. We integrated a bio-psycho-social model of care drawing on rehabilitation literature for long-term health conditions and experiences from our pre-pilot study. Multiple stakeholder meetings were held to refine the intervention which was designed to be deliverable within the UK National Health Service. We adhere to TIDieR guidance for transparent and explicit reporting of telehealth interventions. <br><br><strong>Results</strong>: The final REGAIN online exercise and behavioural support intervention consisted of an initial 1:1 consultation with a trained practitioner, followed by eight online group exercise, and six group support, sessions delivered over eight weeks. Participants could also access an online library of on-demand exercise and support videos.<br><br><strong>Conclusions</strong>: The final REGAIN intervention, combining exercise and behavioural support, is fully manualised with clear pathways to delivery and implementation. It is currently being tested in a randomised controlled trial. The intervention, developed with extensive patient and stakeholder engagement, could be incorporated into existing NHS rehabilitation programmes, should it prove to be clinically and cost-effective for people with long-COVID.</p> <p><strong>Trial registration</strong>: International Standard Randomised Controlled Trial Number (ISRCTN) 11466448: Rehabilitation exercise and psychological support after COVID-19 infection: REGAIN.</p>
Data from: Evaluation of a community health worker home visit intervention to improve child development in South Africa: A cluster-randomized controlled trial
<p><span>This dataset was collected as part of a</span><span> cluster-randomized controlled trial that evaluated the impact of </span>a home visit intervention on child development<span> in Limpopo Province, South Africa. </span><span>Household survey data were collected at baseline and endline. In a subsample of children, neural function was assessed at a lab at endline and at two interim time points. Primary outcomes were: height-for-age z-scores (HAZ) and stunting; child development scores measured using the Malawi Developmental Assessment Tool (MDAT); absolute electroencephalography (EEG) gamma and total power; relative EEG gamma power; and saccadic reaction time (SRT)—</span>an eye-tracking measure of visual processing speed.</p>
Underlying qualitative data for: "What went wrong? A qualitative exploration of the determinants of poor antiretroviral therapy adherence and retention in care among pregnant and postpartum women in the Uganda WiseMama randomized controlled trial"
<p>This dataset is the underlying qualitative data for the paper entitled: "What went wrong? A qualitative exploration of the determinants of poor antiretroviral therapy adherence and retention in care among pregnant and postpartum women in the Uganda WiseMama randomized controlled trial"</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.